EP1321144A4 - Collyre - Google Patents

Collyre

Info

Publication number
EP1321144A4
EP1321144A4 EP01965597A EP01965597A EP1321144A4 EP 1321144 A4 EP1321144 A4 EP 1321144A4 EP 01965597 A EP01965597 A EP 01965597A EP 01965597 A EP01965597 A EP 01965597A EP 1321144 A4 EP1321144 A4 EP 1321144A4
Authority
EP
European Patent Office
Prior art keywords
prostaglandin derivatives
water
liable
ophthalmic solutions
eye drops
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01965597A
Other languages
German (de)
English (en)
Other versions
EP1321144B1 (fr
EP1321144A1 (fr
Inventor
Kenji Morishima
Akio Kimura
Hiroyuki Asada
Masayuki Umeda
Mitsuaki Kuwano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18762864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1321144(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of EP1321144A1 publication Critical patent/EP1321144A1/fr
Publication of EP1321144A4 publication Critical patent/EP1321144A4/fr
Application granted granted Critical
Publication of EP1321144B1 publication Critical patent/EP1321144B1/fr
Priority to CY20111100235T priority Critical patent/CY1113200T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
EP01965597A 2000-09-13 2001-09-13 Collyre Expired - Lifetime EP1321144B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CY20111100235T CY1113200T1 (el) 2000-09-13 2011-02-28 Οφθαλμικες σταγονες

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000277554 2000-09-13
JP2000277554 2000-09-13
PCT/JP2001/007928 WO2002022131A1 (fr) 2000-09-13 2001-09-13 Collyre

Publications (3)

Publication Number Publication Date
EP1321144A1 EP1321144A1 (fr) 2003-06-25
EP1321144A4 true EP1321144A4 (fr) 2009-07-29
EP1321144B1 EP1321144B1 (fr) 2010-12-08

Family

ID=18762864

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01965597A Expired - Lifetime EP1321144B1 (fr) 2000-09-13 2001-09-13 Collyre

Country Status (14)

Country Link
US (4) US20040097592A1 (fr)
EP (1) EP1321144B1 (fr)
KR (1) KR100854056B1 (fr)
CN (1) CN1243548C (fr)
AT (1) ATE490761T1 (fr)
AU (1) AU2001286210A1 (fr)
CA (1) CA2422031C (fr)
CY (2) CY1113200T1 (fr)
DE (1) DE60143615D1 (fr)
DK (1) DK1321144T3 (fr)
ES (1) ES2357551T3 (fr)
NO (1) NO332650B1 (fr)
PT (1) PT1321144E (fr)
WO (1) WO2002022131A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
PT1532981E (pt) * 2002-08-23 2007-12-12 Santen Pharmaceutical Co Ltd Colírios estáveis contendo latanoprost como ingrediente activo
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (fr) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Produit contenant de la prostaglandine
ATE442146T1 (de) 2003-11-07 2009-09-15 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
PT1829545E (pt) * 2004-12-24 2012-05-21 Santen Pharmaceutical Co Ltd Produtos contendo derivado de prostaglandina f2á
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
EP1864666B1 (fr) 2005-03-31 2012-08-15 Asahi Glass Company, Limited Agent protecteur pour la cellule neuronale retinienne contenant un derive de prostaglandine f2 alpha comme ingredient actif
RU2392938C2 (ru) 2005-04-13 2010-06-27 Убе Индастриз, Лтд Защитное средство для нейронных клеток сетчатки, содержащее в качестве активного ингредиента производные индазола
CN103768070A (zh) * 2006-03-13 2014-05-07 株式会社·R-技术上野 水性组合物
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
WO2008123396A1 (fr) * 2007-03-29 2008-10-16 Santen Pharmaceutical Co., Ltd. Préparation de gouttes ophtalmiques de type suspension comprenant de la fluorométholone
EP1985298A1 (fr) * 2007-04-24 2008-10-29 Azad Pharma AG Émulsions ophtalmiques eau dans l'huile contenant des prostaglandines
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
WO2009131164A1 (fr) * 2008-04-23 2009-10-29 大塚製薬株式会社 Préparation de gouttes ophtalmiques et utilisation
EP2127638A1 (fr) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Procédé et composition pour traiter l'hypertension oculaire et le glaucome
EP2328574A1 (fr) * 2008-08-05 2011-06-08 University College Cork-National University of Ireland, Cork Traitement de la dégénérescence de la rétine
RU2482851C2 (ru) * 2009-02-20 2013-05-27 Микро Лабс Лимитед Хранение стабильного продукта простагландина
EP2269575A1 (fr) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Procédé pour améliorer le biodisponibilité du latanoprost
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
ES2391721T3 (es) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído
EP2452669A1 (fr) 2010-10-29 2012-05-16 Omnivision GmbH Composition ophtalmique
EP2567689A1 (fr) * 2011-09-12 2013-03-13 Visiotact Pharma Compositions ophtalmiques contenant des dérivés de prostaglandine 2F alpha et de l'acide hyaluronique
KR102068858B1 (ko) * 2012-06-08 2020-01-21 라이온 가부시키가이샤 점막용 조성물
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法
WO2018033854A1 (fr) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Composition ophtalmique et procédé de traitement de l'hypertension oculaire et du glaucome
EP3603642B1 (fr) 2017-03-27 2024-01-10 Alcon Inc. Préparation pharmaceutique
WO2020013717A1 (fr) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Dispositif de distribution ophtalmique
EP3853317A4 (fr) * 2018-09-21 2022-06-22 PS Therapy Ltd. Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation
EP3871660A4 (fr) 2018-10-25 2022-08-17 Nexmos Co., Ltd. Composition de gouttes oculaires comprenant de l'aptamin c en tant que principe actif

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0603800A1 (fr) * 1992-12-21 1994-06-29 Alcon Laboratories, Inc. Mélanges de prostaglandines pour la thérapie du glaucome
WO2000003736A1 (fr) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Produit de prostaglandine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
KR920002329B1 (ko) * 1987-12-25 1992-03-21 산뗑 세이야꾸 가부시끼가이샤 항-알레르기성 점안제
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5486540A (en) * 1993-10-28 1996-01-23 Allergan, Inc. Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
CN101362518A (zh) * 1999-01-19 2009-02-11 法玛西雅厄普约翰美国公司 γ-照射消毒的聚乙烯包装
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
EP1666043B1 (fr) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Produit contenant de la prostaglandine
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0603800A1 (fr) * 1992-12-21 1994-06-29 Alcon Laboratories, Inc. Mélanges de prostaglandines pour la thérapie du glaucome
WO2000003736A1 (fr) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Produit de prostaglandine

Also Published As

Publication number Publication date
US20160106757A1 (en) 2016-04-21
ATE490761T1 (de) 2010-12-15
NO20031138L (no) 2003-05-12
AU2001286210A1 (en) 2002-03-26
PT1321144E (pt) 2011-03-10
US20070248697A1 (en) 2007-10-25
EP1321144B1 (fr) 2010-12-08
US20040097592A1 (en) 2004-05-20
CY2011007I1 (el) 2014-04-09
ES2357551T3 (es) 2011-04-27
WO2002022131A1 (fr) 2002-03-21
DK1321144T3 (da) 2011-03-07
KR100854056B1 (ko) 2008-08-26
CA2422031A1 (fr) 2003-03-12
CN1457256A (zh) 2003-11-19
CY2011007I2 (el) 2015-08-05
EP1321144A1 (fr) 2003-06-25
DE60143615D1 (de) 2011-01-20
KR20030029981A (ko) 2003-04-16
CN1243548C (zh) 2006-03-01
CA2422031C (fr) 2011-11-15
NO20031138D0 (no) 2003-03-12
NO332650B1 (no) 2012-11-26
US20180353518A1 (en) 2018-12-13
CY1113200T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
EP1321144A4 (fr) Collyre
EP0766970A3 (fr) Procédé et composition de désinfection pour lentilles de contact
WO1997028827A1 (fr) Composition ophtalmique possedant une viscosite adaptee
WO2002026277A3 (fr) Solutions stabilisees de peroxyde d'hydrogene
AU7385094A (en) Pharmaceutical compositions for hardly soluble active substances
CA2124873A1 (fr) Inhibiteur de corrosion contenant de l'iode pour les operations d'acidification dans les champs de petrole
HK1056510A1 (en) Minoxidil-containing preparations
GR3022990T3 (en) Ophthalmic compositions containing a cyclosporin.
ES2045316T3 (es) Preparado lubricante carente de jabon, soluble en agua clara.
JP2005177515A (ja) 多価陽イオンキレート剤を用いて、アイケア用品における原生動物の増殖を抑制する方法
CO4410315A1 (es) Composicion oral que comprende cantidad efectiva de ten- sioactivo y sulfoacetato laurilo de sodio
WO2003009802A3 (fr) Preparations ophtalmiques et dermatologiques antimicrobiennes synergiques contenant du chlore et du peroxyde d'hydrogene
TW266154B (fr)
MXPA03000571A (es) Composicion util para el tratamiento de mastitis de edvino.
CA1331122C (fr) Desinfection de lentilles de contact a la chlorhexidine
IL111625A0 (en) Phosphoric esters for use as crystallisation inhibitors
EP0497001A3 (en) Oxidized-type glutathione alkyl ester
EP0349153A3 (fr) Système stabilisant les compositions liquides d'eau oxygénée et compositions stabilisées de cette manière
CA2137578A1 (fr) Methode de stabilisation de preparations pour verres de contact
CA2090911A1 (fr) Formulations pharmaceutiques aqueuses a base de cromoglycate sodique
CA2390996A1 (fr) Solutions de nettoyage aqueuses contenant des niveaux eleves de n-alkyl-2-pyrrolidine
GB0123382D0 (en) Water soluble package and liquid contents thereof
JP2927294B2 (ja) 液体漂白剤組成物
AU2001242398A1 (en) Contact lens treating method and composition
RU98104644A (ru) Ингибитор коррозии нефтепромыслового оборудования

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030401

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090625

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20090619BHEP

Ipc: A61K 47/10 20060101ALI20090619BHEP

Ipc: A61K 47/18 20060101ALI20090619BHEP

Ipc: A61K 47/44 20060101ALI20090619BHEP

Ipc: A61K 47/34 20060101ALI20090619BHEP

Ipc: A61K 31/5575 20060101ALI20090619BHEP

Ipc: A61K 9/08 20060101AFI20090619BHEP

17Q First examination report despatched

Effective date: 20091015

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60143615

Country of ref document: DE

Date of ref document: 20110120

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20110302

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2357551

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110427

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110400573

Country of ref document: GR

Effective date: 20110412

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ASAHI GLASS COMPANY, LIMITED

Owner name: SANTEN PHARMACEUTICAL CO., LTD.

26N No opposition filed

Effective date: 20110909

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60143615

Country of ref document: DE

Effective date: 20110909

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60143615

Country of ref document: DE

Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: SANTEN PHARMACEUTICAL CO., LTD., JP

Free format text: FORMER OWNER: SANTEN PHARMACEUTICAL CO., LTD., JP

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: AGC INC.

Effective date: 20180918

Ref country code: ES

Ref legal event code: PC2A

Effective date: 20180918

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: SANTEN PHARMACEUTICAL CO., LTD.; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF LEGAL ENTITY; FORMER OWNER NAME: SANTEN PHARMACEUTICAL CO., LTD.

Effective date: 20180815

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: AGC INC.; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE

Effective date: 20180822

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: SANTEN PHARMACEUTICAL CO. LTD.; JP

Free format text: FORMER OWNER: ASAHI GLASS COMPANY LIMITED

Effective date: 20181002

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60143615

Country of ref document: DE

Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 60143615

Country of ref document: DE

Owner name: AGC INC., JP

Free format text: FORMER OWNERS: ASAHI GLASS CO., LTD., TOKIO/TOKYO, JP; SANTEN PHARMACEUTICAL CO., LTD, OSAKA, JP

Ref country code: DE

Ref legal event code: R081

Ref document number: 60143615

Country of ref document: DE

Owner name: SANTEN PHARMACEUTICAL CO., LTD, JP

Free format text: FORMER OWNERS: ASAHI GLASS CO., LTD., TOKIO/TOKYO, JP; SANTEN PHARMACEUTICAL CO., LTD, OSAKA, JP

REG Reference to a national code

Ref country code: AT

Ref legal event code: HC

Ref document number: 490761

Country of ref document: AT

Kind code of ref document: T

Owner name: AGC INC., JP

Effective date: 20190312

Ref country code: AT

Ref legal event code: HC

Ref document number: 490761

Country of ref document: AT

Kind code of ref document: T

Owner name: SANTEN PHARMACEUTICAL CO., LTD., JP

Effective date: 20190312

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20200814

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200901

Year of fee payment: 20

Ref country code: IE

Payment date: 20200909

Year of fee payment: 20

Ref country code: LU

Payment date: 20200824

Year of fee payment: 20

Ref country code: CY

Payment date: 20200904

Year of fee payment: 20

Ref country code: TR

Payment date: 20200909

Year of fee payment: 20

Ref country code: MC

Payment date: 20200826

Year of fee payment: 20

Ref country code: GB

Payment date: 20200902

Year of fee payment: 20

Ref country code: GR

Payment date: 20200813

Year of fee payment: 20

Ref country code: FR

Payment date: 20200812

Year of fee payment: 20

Ref country code: DK

Payment date: 20200910

Year of fee payment: 20

Ref country code: FI

Payment date: 20200909

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200916

Year of fee payment: 20

Ref country code: BE

Payment date: 20200817

Year of fee payment: 20

Ref country code: SE

Payment date: 20200910

Year of fee payment: 20

Ref country code: AT

Payment date: 20200825

Year of fee payment: 20

Ref country code: IT

Payment date: 20200812

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20201015

Year of fee payment: 20

Ref country code: PT

Payment date: 20200929

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60143615

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20210912

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20210913

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20210913

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20210912

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 490761

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20210921

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20210912

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20211227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20210913

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20210914